v3.22.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Cash flows from operating activities      
Net loss including non-controlling interests $ (570) $ (6,788) $ (8,512)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 902 575 472
Bad debt expense 109 76 92
Stock-based compensation 1,168 827 4,596
Gain on extinguishment of convertible notes and settlement of derivatives 0 0 (444)
Gain from sale of investments (413) 0 0
Gain on business divestitures, net (1,684) (204) 0
Deferred income taxes (692) (266) (88)
Impairment of debt and equity securities 0 1,690 0
Impairments of goodwill, long-lived assets and other assets 116 404 0
Loss from equity method investments 37 34 34
Unrealized (gain) loss on debt and equity securities, net (1,142) 125 (2)
Unrealized foreign currency transactions 38 48 16
Other 4 2 15
Change in assets and liabilities, net of impact of business acquisitions and disposals:      
Accounts receivable (597) 142 (407)
Prepaid expenses and other assets (236) 94 (478)
Collateral held by insurer 860 339 (1,199)
Operating lease right-of-use assets 165 341 201
Accounts payable 90 (133) 95
Accrued insurance reserves 516 (3) 481
Accrued expenses and other liabilities 1,068 83 960
Operating lease liabilities (184) (131) (153)
Net cash used in operating activities (445) (2,745) (4,321)
Cash flows from investing activities      
Purchases of property and equipment (298) (616) (588)
Purchases of non-marketable equity securities (982) (10) (100)
Purchases of marketable securities (1,113) (2,101) (441)
Proceeds from maturities and sales of marketable securities 2,291 1,360 2
Proceeds from sale of non-marketable equity securities 500 0 0
Proceeds from sale of equity method investments 1,000 0 0
Proceeds from business disposal, net of cash divested 0 0 293
Acquisition of businesses, net of cash acquired (2,314) (1,471) (7)
Return of capital from equity method investee 0 91 0
Purchase of notes receivables (297) (185) 0
Other investing activities 12 63 51
Net cash used in investing activities (1,201) (2,869) (790)
Cash flows from financing activities      
Proceeds from issuance of common stock upon initial public offering, net of offering costs 0 0 7,973
Taxes paid related to net share settlement of equity awards (27) (17) (1,573)
Proceeds from issuance of common stock related to private placement 0 0 500
Proceeds from issuance and sale of subsidiary preferred stock units 675 247 1,000
Proceeds from the issuance of common stock under the Employee Stock Purchase Plan 107 125 49
Issuance of term loan and notes, net of issuance costs 1,484 2,628 1,189
Principal repayment on term loan and notes (27) (527) (27)
Principal repayment on Careem Notes (307) (891) 0
Principal payments on finance leases (226) (224) (138)
Other financing activities 101 38 (34)
Net cash provided by financing activities 1,780 1,379 8,939
Effect of exchange rate changes on cash and cash equivalents, and restricted cash and cash equivalents (69) (92) (4)
Net increase (decrease) in cash and cash equivalents, and restricted cash and cash equivalents 65 (4,327) 3,824
Cash and cash equivalents, and restricted cash and cash equivalents      
Beginning of period   7,391 12,067
Reclassification from (to) assets held for sale during the period 349 (349) 34
End of period, excluding cash classified within assets held for sale 7,805 7,391 12,067
Cash paid for:      
Interest, net of amount capitalized 449 412 332
Income taxes, net of refunds 87 82 133
Non-cash investing and financing activities:      
Conversion of redeemable convertible preferred stock to common stock upon initial public offering 0 0 14,224
Conversion of convertible notes to common stock upon initial public offering 0 0 4,229
Conversion of convertible notes to common stock related to Careem 232 0 0
Finance lease obligations 184 196 251
Common stock issued in connection with acquisitions 1,868 3,898 9
Ownership interest received in exchange for divestitures 1,018 171 0
Issuance of Careem Notes including the holdback amount $ 0 $ 1,634 $ 0